Drugs / YR011
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT07285967 Comparator | Apr → Sep 2026 overdue | — | Hangzhou Yirui Pharmaceutical Technology Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YR011 | “This is a Phase I clinical trial (protocol number: YR-011-B01) sponsored by Hangzhou Yirui Pharmaceutical Technology Co., Ltd., focusing on the novel oral small-molecule drug...” NCT07285967 ↗ |
| Action | Inhibit | “a Kv1.3 channel blocker” NCT07285967 ↗ |
| Modality | Small molecule | “novel oral small-molecule drug YR011” NCT07285967 ↗ |
| Route | Oral | “following oral administration” NCT07285967 ↗ |